Santa Fe Springs, CA 2/9/17—Applied BioCode, a provider of Barcoded Magnetic Bead and detection systems for multiplexed nucleic acid and protein detection assays, has completed an IPO on the Taiwan Emerging Market Stock Exchange. The company operates as a registered Cayman Island corporation, and has facilities in the US and Taiwan. “This will enable Applied BioCode to gain access to additional capital in order to accelerate the commercialization of the BioCode MDx 3000 High Volume Molecular Diagnostics System with 18-plex Gastrointestinal Panel into the US market, and we anticipate FDA clearance later this year,” stated Applied BioCode President Dr. Winston Ho.

The company’s technology utilizes up to 4,096 digital barcodes. For the research market, Applied BioCodes provides the BioCode 100A and 2000 Analyzers, as well as cytokine/chemokine multiplex immunoassays. For this market, it has licensed its technology to Molecular Devices and LGC (formerly Douglas Scientific).